<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Esophageal multichannel intraluminal impedance testing</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Esophageal multichannel intraluminal impedance testing</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Esophageal multichannel intraluminal impedance testing</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Radu Tutuian, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nicholas J Talley, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 04, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Multichannel intraluminal impedance (MII) is a catheter-based method to detect intraluminal bolus movement within the esophagus. MII is performed in combination with manometry or pH testing. When combined with manometry, it provides information on the functional (ie, bolus transit) component of manometrically detected contractions. When combined with pH testing, it allows for the detection of gastroesophageal reflux independent of pH (ie, both acid and non-acid reflux).</p><p>This topic will review the principles, technique, and results of esophageal MII testing, and their clinical implications. Motility testing and high-resolution esophageal manometry are discussed in detail, separately. (See  <a class="medical medical_review" href="/z/d/html/17125.html" rel="external">"High resolution manometry"</a> and  <a class="medical medical_review" href="/z/d/html/2238.html" rel="external">"Overview of gastrointestinal motility testing"</a> and  <a class="medical medical_review" href="/z/d/html/2256.html" rel="external">"Distal esophageal spasm and hypercontractile esophagus"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PRINCIPLES OF IMPEDANCE TESTING</span><span class="headingEndMark"> — </span>Impedance testing is based on the measurement of changes in resistance to alternating electrical current when a bolus passes by a pair of metallic rings mounted on a catheter. In an empty tubular organ such as the esophagus, the electrical current between the two rings is conducted by the few ions present in and on the mucosa. Liquid-containing boluses with an increased number of ions have a higher conductivity and, when entering the impedance-measuring segment, will lower the impedance to a nadir value. The impedance stays at its nadir as long as the bolus is present in the segment, returning to baseline once the bolus is cleared by a contraction. The contraction produces a slight increase in impedance above the baseline due to a decrease in luminal cross-section. Gas passing transiently by the impedance-measuring segments will produce a rapid and high (usually &gt;3000 Ohms) rise in the impedance since it has poor electrical conductance.</p><p>Measuring impedance at multiple sites (multichannel) allows for determination of the direction of bolus movement based upon temporal differences in bolus entry and exit. Bolus entries progressing from proximal to distal indicate antegrade bolus movement, while bolus entries progressing from distal to proximal indicate retrograde bolus movement  (<a class="graphic graphic_waveform graphicRef56477" href="/z/d/graphic/56477.html" rel="external">waveform 1</a>).</p><p class="headingAnchor" id="H3"><span class="h1">COMBINED MULTICHANNEL INTRALUMINAL IMPEDANCE AND MANOMETRY</span><span class="headingEndMark"> — </span>Standard manometry does not demonstrate whether a contraction results in actual bolus passage. Combined multichannel intraluminal impedance with esophageal manometry (MII-EM) is a test of esophageal function as it provides information about both pressures and bolus transit within the esophagus.</p><p class="headingAnchor" id="H4"><span class="h2">Indications</span><span class="headingEndMark"> — </span>The indications for MII-EM are similar to those for esophageal manometry (see  <a class="medical medical_review" href="/z/d/html/2238.html" rel="external">"Overview of gastrointestinal motility testing", section on 'Esophagus'</a>): </p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation of patients with dysphagia, noncardiac chest pain, and/or heartburn/regurgitation</p><p class="bulletIndent1"><span class="glyph">●</span>Preoperative evaluation before antireflux surgery or endoscopic antireflux procedures </p><p class="bulletIndent1"><span class="glyph">●</span>Location of the lower esophageal sphincter (LES) prior to pH catheter placement </p><p></p><p>The role of MII-EM in the diagnosis of extra-esophageal disorders related to gastroesophageal reflux disease, such as chronic cough, has not been established [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/6852.html" rel="external">"Laryngopharyngeal reflux in adults: Evaluation, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H173472138"><span class="h2">Patient protocol</span><span class="headingEndMark"> — </span>Patients are asked to fast for four to six hours, after which the combined MII-EM catheter is inserted transnasally through the esophagus into the stomach. The procedure is performed in an outpatient setting. After successful catheter placement, 10 liquid and 10 viscous (applesauce) swallows are given, each 30 seconds apart. </p><p>The impedance of water can vary depending upon its source, leading to potential impedance artifacts. Normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> is preferred over plain water since it has a standardized ionic concentration allowing reliable identification of bolus presence by impedance. Impedance testing with swallows of a viscous solution may be more sensitive than water swallowing in identifying esophageal dysmotility [<a href="#rid2">2,3</a>].</p><p class="headingAnchor" id="H173472167"><span class="h2">Technique</span><span class="headingEndMark"> — </span>The LES is located by stationary pull-through technique, and the most distal sensor is placed in the high-pressure zone of the LES. The design of the catheter determines the location of the pressure and impedance-measuring segments. The conventional manometry nine-channel esophageal function testing catheter has five pressure sensors 5 cm apart and four impedance-measuring segments straddling the four proximal pressure sensors, allowing pressure measurements in the LES and at 5, 10, 15, and 20 cm above the LES. Impedance-measuring segments are centered at 5, 10, 15, and 20 cm above the LES. High-resolution impedance manometry systems use multiple pressure and impedance sites separated by 1 to 2 cm to more closely view pressure and bolus transit from pharynx to stomach. Data analysis is performed using dedicated software. (See  <a class="medical medical_review" href="/z/d/html/17125.html" rel="external">"High resolution manometry", section on 'Technique'</a> and  <a class="medical medical_review" href="/z/d/html/2238.html" rel="external">"Overview of gastrointestinal motility testing", section on 'Esophageal manometry'</a>.)</p><p class="headingAnchor" id="H173472451"><span class="h2">Impedance results parameters</span><span class="headingEndMark"> — </span>Impedance measurements allow identification of the bolus in a given segment of the esophagus. Bolus entry is considered at the 50 percent drop in impedance from baseline relative to nadir and bolus exit at the 50 percent recovery point from nadir to baseline. Measuring bolus presence at different levels in the esophagus individual swallows are classified by MII as showing:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complete bolus transit </strong>–<strong> </strong>Bolus transit is defined as complete<strong> </strong>if bolus entry occurs at the most proximal site (20 cm above the LES) and bolus exit points are recorded in all three distal impedance-measuring sites (ie, 15, 10, and 5 cm above the LES).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incomplete bolus transit </strong>–<strong> </strong>Bolus transit is defined as incomplete<strong> </strong>if bolus entry occurs at the most proximal site (20 cm above the LES) and bolus exit is not identified at any one of the three distal impedance-measuring sites.</p><p></p><p>The number of swallows with complete and incomplete bolus transit can be used to assess bolus transit.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normal esophageal bolus transit </strong>– At least 70 percent of individual liquid swallows have complete bolus transit and at least 60 percent of individual viscous swallows have complete bolus transit.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Esophageal transit abnormality</strong> – An esophageal transit abnormality is considered to be present if 30 percent or more of liquid swallows have incomplete bolus transit or if 40 percent or more of viscous swallows have incomplete bolus transit [<a href="#rid4">4</a>].</p><p></p><p>The interpretation of the manometric pressure and other parameters obtained by conventional and high-resolution manometry is discussed in detail, separately. (See  <a class="medical medical_review" href="/z/d/html/2256.html" rel="external">"Distal esophageal spasm and hypercontractile esophagus"</a> and  <a class="medical medical_review" href="/z/d/html/17125.html" rel="external">"High resolution manometry"</a>.)</p><p class="headingAnchor" id="H173472266"><span class="h2">Clinical application</span><span class="headingEndMark"> — </span>Combined MII-EM has a high sensitivity for detection of esophageal motility disorders. In patients with nonobstructive and postoperative dysphagia, MII-EM may have a higher sensitivity for detection of an underlying bolus transit abnormality as compared with manometry alone [<a href="#rid2">2,4,5</a>]. (See <a class="local">'Impedance results parameters'</a> above.)</p><p>Functional information provided by MII-EM allows for categorization of transit abnormalities into those with a pressure-only defect and those with a pressure and bolus transit defect  (<a class="graphic graphic_table graphicRef81342" href="/z/d/graphic/81342.html" rel="external">table 1</a>). Studies in patients with esophageal motility abnormalities suggest that patients with achalasia or scleroderma have abnormal bolus transit, while over 95 percent of patients with normal manometry, nutcracker esophagus, or isolated LES abnormalities (ie, hypertensive LES, hypotensive LES, or poorly relaxing LES) have normal bolus transit [<a href="#rid6">6,7</a>].</p><p>Combined MII-EM can also assess the degree of functional defect in patients with manometrically defined ineffective esophageal motility and distal esophageal spasm [<a href="#rid8">8,9</a>]. However, additional studies are needed to evaluate the prognostic values of pressure and bolus transit abnormalities detected on MII-EM.</p><p class="headingAnchor" id="H7"><span class="h1">COMBINED MULTICHANNEL INTRALUMINAL IMPEDANCE AND PH</span><span class="headingEndMark"> — </span>The addition of multichannel intraluminal impedance (MII) to pH testing has the advantage of detection of non-acid gastroesophageal reflux (GER) in addition to acid reflux.</p><p class="headingAnchor" id="H8"><span class="h2">Indications</span></p><p class="bulletIndent1"><span class="glyph">●</span>To quantify and characterize GER, especially in patients with an incomplete or no response to acid-suppressive therapy with a proton pump inhibitor (PPI) and who have normal endoscopic findings [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/2239.html" rel="external">"Approach to refractory gastroesophageal reflux disease in adults", section on 'Esophageal impedance pH testing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To evaluate patients with atypical GER symptoms (eg, chronic cough, dysphonia/hoarseness, globus pharyngeus, or nonproductive throat clearing) [<a href="#rid11">11-13</a>]. (See  <a class="medical medical_review" href="/z/d/html/6852.html" rel="external">"Laryngopharyngeal reflux in adults: Evaluation, diagnosis, and management"</a> and  <a class="medical medical_review" href="/z/d/html/2240.html" rel="external">"Globus sensation"</a>.)</p><p></p><p class="headingAnchor" id="H173472356"><span class="h2">Patient protocol</span><span class="headingEndMark"> — </span>Patients are instructed to fast for four to six hours prior to probe insertion and to have a "usual" day following probe insertion. Patients are provided a diary to record the time and content of meals, time of upright and recumbent periods, time of administration of acid-suppressive medication, and time of symptoms and other relevant events (eg, correction of catheter position, disconnection of the skin electrode). Relevant symptoms should be agreed upon before the study begins and can be assigned to "event" buttons on the recording device, which should then be pressed with the occurrence of each symptom. </p><p>There are no clear guidelines on whether or not diet restrictions should be given, and the practice varies by center. We encourage patients to induce as many symptoms as they can by either ingesting foods and/or doing activities known to produce symptoms. The following day the patient returns the logger and diary, and data are downloaded. </p><p class="headingAnchor" id="H173472339"><span class="h3">Testing on or off proton pump inhibitors</span><span class="headingEndMark"> — </span>The decision to perform combined MII and pH (MII-pH) testing on or off proton pump inhibitor (PPI) therapy should be based on the underlying indication for testing. In patients with refractory GER disease (GERD) symptoms, MII-pH testing is intended to detect weakly acidic (non-acid) reflux as a cause of ongoing symptoms [<a href="#rid10">10,14,15</a>]. Therefore, PPI therapy is usually continued for the examination. In such patients, we suggest high-dose acid-suppressive therapy (ie, a PPI at least twice daily before meals) for at least one week before combined MII-pH testing. Patients taking acid-suppressive therapy should be instructed to take the medications as prescribed, even on the day of testing. In patients in whom it is unclear if GERD is the cause of their symptoms, we perform MII-pH testing off PPIs to optimize the chance of detecting reflux events. </p><p class="headingAnchor" id="H173472350"><span class="h2">Technique</span><span class="headingEndMark"> — </span>The combined MII-pH probe is placed transnasally into the esophagus. Available probes (6 impedance probes and 2 pH probes) are 2.1 mm in diameter (similar to conventional pH probes) and allow for pH sensors to be placed 5 cm above the lower esophageal sphincter (LES) and 10 cm below the LES, with impedance-measuring segments at 3, 5, 7, and 9 cm above the LES in the distal esophagus and at 15 and 17 cm above the LES in the proximal esophagus  (<a class="graphic graphic_figure graphicRef68998" href="/z/d/graphic/68998.html" rel="external">figure 1</a>). While these probes are preferred to investigate patients on PPI therapy, there are also probes with only 6 impedance-measuring segments and one pH sensor (placed at 5 cm above the LES). The later probe is sufficient when performing measurement off PPI therapy. Data analysis is performed using dedicated software. The principles of data analysis are the same regardless of which system is used.</p><p class="headingAnchor" id="H173473068"><span class="h2">Impedance-pH results parameters</span><span class="headingEndMark"> — </span>In addition to providing information on conventional pH parameters, combined MII-pH monitoring also provides information on the following parameters:</p><p class="headingAnchor" id="H3075864"><span class="h3">Refluxate composition</span><span class="headingEndMark"> — </span>Reflux episodes are classified by MII as containing gas, liquid, or both, based upon different impedance patterns. Air conducts electricity poorly and therefore has very high impedance, whereas liquid gastric contents have low impedance. Mixed reflux events are a combination of both a liquid and gas pattern. </p><p class="headingAnchor" id="H3075870"><span class="h3">Proximal extent of reflux</span><span class="headingEndMark"> — </span>The proximal extent of a reflux event is defined by the most proximal impedance-measuring segment reached by the liquid component of the reflux episode. Gas reflux events are not assigned a proximal extent since they typically penetrate the upper esophageal sphincter and are eliminated.</p><p class="headingAnchor" id="H3076006"><span class="h3">Number of acid and non-acid reflux episodes</span><span class="headingEndMark"> — </span>Combined MII-pH defines the number of MII-GER episodes as the total number of MII-detected episodes.</p><p class="headingAnchor" id="H3075876"><span class="h3">Refluxate contact time</span><span class="headingEndMark"> — </span>Refluxate presence time<strong> </strong>is defined as the total amount of time (absolute or percent of the study period) liquid-containing refluxate is detected by the impedance-measuring segment located at 5 cm above the LES.</p><p class="headingAnchor" id="H3075883"><span class="h3">Refluxate clearance time</span><span class="headingEndMark"> — </span>Reflux clearance time<strong> </strong>is defined as the average duration that liquid-containing MII-refluxate is present 5 cm above the LES.</p><p class="headingAnchor" id="H1080127231"><span class="h3">Reflux pH</span><span class="headingEndMark"> — </span>The abovementioned parameters are further categorized into acid and non-acid based upon the pH changes recorded at the time when the reflux occurred. According to the position of the subject at the time the GER occurs, these parameters are further separated into upright and recumbent.</p><p class="bulletIndent1"><span class="glyph">●</span>An acid reflux event is defined as an event during which there is a drop of pH to below 4. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Non-acid reflux is defined as an event during which the pH stays above 4  (<a class="graphic graphic_figure graphicRef55868" href="/z/d/graphic/55868.html" rel="external">figure 2</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Weakly acidic (non-acid) reflux is used to define reflux episodes with pH 4 to 7. Weakly alkaline is defined as reflux episodes with pH &gt;7 [<a href="#rid16">16</a>]. Since weakly alkaline reflux episodes (pH &gt;7) are rare, from a practical point of view the terms "weakly acidic" and "non-acid" describe the same event (ie, reflux episodes with pH &gt;4).</p><p></p><p class="headingAnchor" id="H3076144"><span class="h2">Interpretation of results</span></p><p class="headingAnchor" id="H3076150"><span class="h3">Reference values</span><span class="headingEndMark"> — </span>Overall study interpretation is based initially upon normative data from healthy volunteers [<a href="#rid17">17</a>]. In the postprandial period, acid-suppressive therapy primarily changes the ratio of acid versus non-acid reflux episodes [<a href="#rid18">18</a>]. Acid-suppressive therapy also decreases the total number of reflux episodes, presumably by reducing the total amount of gastric secretion [<a href="#rid19">19,20</a>]. As a result, different normal values are used when interpreting the total number of reflux episodes in patients "off" and "on" acid-suppressive therapy  (<a class="graphic graphic_table graphicRef56522" href="/z/d/graphic/56522.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H3075890"><span class="h3">Symptom correlation measures</span><span class="headingEndMark"> — </span>The main parameter used to interpret MII-pH monitoring studies is the association of symptoms with GER episodes (acid and non-acid). Two main indices have been used to assess this association.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptom index (SI) </strong>– The SI represents the number of symptoms associated with reflux occurring in the preceding five-minute interval divided by the total number of symptoms recorded by a patient during the monitoring period expressed in percent. Patients with a positive test (SI ≥50 percent) are considered to have symptomatic GER on PPI therapy. By contrast, patients with SI &lt;50 percent are considered to have a negative study and persistent symptoms on PPI therapy are due to causes other than GER. However, the validity of these cutoffs has not been established.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptom association probability (SAP) </strong>– For the calculation of the SAP, the total measuring time is subdivided into two-minute intervals. A contingency table with four fields (number of intervals with GER and symptoms, number of intervals with GER without symptoms, number of intervals without GER and with symptoms, and number of intervals without both GER and symptoms) is used to assess correlation with the Fisher exact test [<a href="#rid21">21</a>]. A positive SAP (&gt;95 percent) is interpreted as a good temporal association between GER and the recorded symptom. </p><p></p><p class="headingAnchor" id="H173473110"><span class="h2">Clinical application</span><span class="headingEndMark"> — </span>MII-pH has a high sensitivity for detecting all types of reflux episodes. It is primarily used to evaluate patients with persistent symptoms despite PPI therapy in order to clarify the association of symptoms with reflux events [<a href="#rid16">16,22</a>]. Studies using combined MII-pH have demonstrated that approximately one-half of patients with persistent symptoms on PPI therapy do not have a temporal correlation between their symptoms and any type of reflux [<a href="#rid1">1,13,23-29</a>]. In addition, approximately 40 percent of patients with persistent symptoms on PPI therapy have a temporal association between their symptoms and reflux, primarily of the non-acid type. However, whether the improved understanding of symptoms to reflux and non-reflux events translates into better health outcomes has not been well established. (See <a class="local">'Combined multichannel intraluminal impedance and pH'</a> above and  <a class="medical medical_review" href="/z/d/html/2244.html" rel="external">"Non-acid reflux: Clinical manifestations, diagnosis, and management", section on 'Diagnostic evaluation'</a>.) </p><p class="headingAnchor" id="H3075986"><span class="h1">COMPLICATIONS AND CONTRAINDICATIONS</span><span class="headingEndMark"> — </span>Complications of multichannel intraluminal impedance testing are extremely rare but could include infection, bleeding, and trauma to the nasopharynx or esophagus. Relative contraindications for placement of a transnasal MII catheter include prior nasal surgery or trauma, coagulopathy, and the concurrent use of anticoagulants [<a href="#rid30">30</a>]. Safety data on the use of impedance in patients with implantable cardiac defibrillators and pacemakers are lacking. However, interference of pacemakers/automatic implantable cardioverter-defibrillators with the impedance measurement or triggering of defibrillation has not been reported.</p><p class="headingAnchor" id="H1376967276"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118166.html" rel="external">"Society guideline links: Esophageal manometry and pH testing"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Multichannel intraluminal impedance (MII) is a catheter-based method to detect intraluminal bolus movement within the esophagus. MII is performed in combination with manometry or pH testing. (See <a class="local">'Introduction'</a> above and <a class="local">'Principles of impedance testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>MII combined with esophageal manometry (MII-EM) provides information about both pressures and bolus transit within the esophagus. Indications for MII-EM include evaluation of patients with dysphagia, noncardiac chest pain, heartburn/regurgitation, and preoperative evaluation before antireflux surgery or endoscopic antireflux procedures. (See <a class="local">'Indications'</a> above and <a class="local">'Clinical application'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Swallows are classified by MII-EM as showing complete bolus transit if bolus entry occurs at the most proximal site (20 cm above the lower esophageal sphincter [LES]) and bolus exit points are recorded in all three distal impedance-measuring sites (ie, 15, 10, and 5 cm above the LES), and incomplete bolus transit if bolus exit is not identified at any one of the three distal impedance-measuring sites. An esophageal transit abnormality is considered to be present if 30 percent or more of liquid swallows have incomplete bolus transit or if 40 percent or more of viscous swallows have incomplete bolus transit. (See <a class="local">'Impedance results parameters'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Combined MII and pH (MII-pH) testing can detect both acid and non-acid gastroesophageal reflux (GER). Indications for MII-pH include quantification and characterization of GER, especially in patients with an incomplete or no response to acid-suppressive therapy with a proton pump inhibitor (PPI) and who have normal endoscopic findings and evaluation of atypical GER symptoms (eg, chronic cough). (See <a class="local">'Indications'</a> above and <a class="local">'Clinical application'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The decision to perform MII-pH testing on or off PPI therapy should be based on the underlying indication for testing. In patients with refractory GER disease (GERD) symptoms, MII-pH testing is intended to detect weakly acidic (non-acid) reflux as a cause of ongoing symptoms. In such patients we administer high-dose acid-suppressive therapy (ie, a PPI at least twice daily before meals) for at least one week before combined MII-pH testing. In patients in whom it is unclear if GERD is the cause of their symptoms, we perform MII-pH testing off PPIs to optimize the chance of detecting reflux events. (See <a class="local">'Patient protocol'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In MII-pH studies, reflux presence, distribution, composition, and clearance are primarily detected by MII and characterized as acid versus non-acid based upon pH change. MII determines refluxate clearance time, while pH measures acid clearance time. Overall study interpretation is based initially upon normative data from healthy volunteers and association of symptoms with GER episodes (acid and non-acid). (See <a class="local">'Impedance-pH results parameters'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complications of MII testing include infection, bleeding, and trauma to the nasopharynx or esophagus. Relative contraindications for placement of a transnasal MII catheter include prior nasal surgery or trauma, coagulopathy, and the concurrent use of anticoagulants. (See <a class="local">'Complications and contraindications'</a> above.)</p><p></p><p class="headingAnchor" id="H1829179139"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Donald O Castell, MD, now deceased, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sifrim D, Dupont L, Blondeau K, et al. Weakly acidic reflux in patients with chronic unexplained cough during 24 hour pressure, pH, and impedance monitoring. Gut 2005; 54:449.</a></li><li><a class="nounderline abstract_t">Koya DL, Agrawal A, Freeman JE, Castell DO. Impedance detected abnormal bolus transit in patients with normal esophageal manometry. Sensitive indicator of esophageal functional abnormality? Dis Esophagus 2008; 21:563.</a></li><li><a class="nounderline abstract_t">Clayton SB, Rife C, Kalbfleisch JH, Castell DO. Viscous impedance is an important indicator of abnormal esophageal motility. Neurogastroenterol Motil 2013; 25:563.</a></li><li><a class="nounderline abstract_t">Tutuian R, Vela MF, Balaji NS, et al. Esophageal function testing with combined multichannel intraluminal impedance and manometry: multicenter study in healthy volunteers. Clin Gastroenterol Hepatol 2003; 1:174.</a></li><li><a class="nounderline abstract_t">Yigit T, Quiroga E, Oelschlager B. Multichannel intraluminal impedance for the assessment of post-fundoplication dysphagia. Dis Esophagus 2006; 19:382.</a></li><li><a class="nounderline abstract_t">Tutuian R, Castell DO. Combined multichannel intraluminal impedance and manometry clarifies esophageal function abnormalities: study in 350 patients. Am J Gastroenterol 2004; 99:1011.</a></li><li><a class="nounderline abstract_t">Conchillo JM, Nguyen NQ, Samsom M, et al. Multichannel intraluminal impedance monitoring in the evaluation of patients with non-obstructive Dysphagia. Am J Gastroenterol 2005; 100:2624.</a></li><li><a class="nounderline abstract_t">Tutuian R, Castell DO. Clarification of the esophageal function defect in patients with manometric ineffective esophageal motility: studies using combined impedance-manometry. Clin Gastroenterol Hepatol 2004; 2:230.</a></li><li><a class="nounderline abstract_t">Tutuian R, Mainie I, Agrawal A, et al. Symptom and function heterogenicity among patients with distal esophageal spasm: studies using combined impedance-manometry. Am J Gastroenterol 2006; 101:464.</a></li><li><a class="nounderline abstract_t">Hirano I, Richter JE, Practice Parameters Committee of the American College of Gastroenterology. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol 2007; 102:668.</a></li><li><a class="nounderline abstract_t">Ford CN. Evaluation and management of laryngopharyngeal reflux. JAMA 2005; 294:1534.</a></li><li><a class="nounderline abstract_t">Oelschlager BK, Quiroga E, Isch JA, Cuenca-Abente F. Gastroesophageal and pharyngeal reflux detection using impedance and 24-hour pH monitoring in asymptomatic subjects: defining the normal environment. J Gastrointest Surg 2006; 10:54.</a></li><li><a class="nounderline abstract_t">Tutuian R, Mainie I, Agrawal A, et al. Nonacid reflux in patients with chronic cough on acid-suppressive therapy. Chest 2006; 130:386.</a></li><li><a class="nounderline abstract_t">Pritchett JM, Aslam M, Slaughter JC, et al. Efficacy of esophageal impedance/pH monitoring in patients with refractory gastroesophageal reflux disease, on and off therapy. Clin Gastroenterol Hepatol 2009; 7:743.</a></li><li><a class="nounderline abstract_t">Gyawali CP, Yadlapati R, Fass R, et al. Updates to the modern diagnosis of GERD: Lyon consensus 2.0. Gut 2024; 73:361.</a></li><li><a class="nounderline abstract_t">Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004; 53:1024.</a></li><li><a class="nounderline abstract_t">Shay S, Tutuian R, Sifrim D, et al. Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol 2004; 99:1037.</a></li><li><a class="nounderline abstract_t">Vela MF, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001; 120:1599.</a></li><li><a class="nounderline abstract_t">Tutuian R, Mainie I, Agrawal A, et al. Normal values for ambulatory 24-h combined impedance-pH monitoring on acid suppressive therapy. Gastroenterology 2006; 130 Suppl 2:A171.</a></li><li><a class="nounderline abstract_t">Zerbib F, Roman S, Bruley Des Varannes S, et al. Normal values of pharyngeal and esophageal 24-hour pH impedance in individuals on and off therapy and interobserver reproducibility. Clin Gastroenterol Hepatol 2013; 11:366.</a></li><li><a class="nounderline abstract_t">Weusten BL, Roelofs JM, Akkermans LM, et al. The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data. Gastroenterology 1994; 107:1741.</a></li><li><a class="nounderline abstract_t">Bredenoord AJ, Weusten BL, Timmer R, Smout AJ. Reproducibility of multichannel intraluminal electrical impedance monitoring of gastroesophageal reflux. Am J Gastroenterol 2005; 100:265.</a></li><li><a class="nounderline abstract_t">Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006; 55:1398.</a></li><li><a class="nounderline abstract_t">Zerbib F, Roman S, Ropert A, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006; 101:1956.</a></li><li><a class="nounderline abstract_t">Mainie I, Tutuian R, Agrawal A, et al. Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication. Br J Surg 2006; 93:1483.</a></li><li><a class="nounderline abstract_t">Sharma N, Agrawal A, Freeman J, et al. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol 2008; 6:521.</a></li><li><a class="nounderline abstract_t">Kline MM, Ewing M, Simpson N, Laine L. The utility of intraluminal impedance in patients with gastroesophageal reflux disease-like symptoms but normal endoscopy and 24-hour pH testing. Clin Gastroenterol Hepatol 2008; 6:880.</a></li><li><a class="nounderline abstract_t">Tutuian R, Vela MF, Hill EG, et al. Characteristics of symptomatic reflux episodes on Acid suppressive therapy. Am J Gastroenterol 2008; 103:1090.</a></li><li><a class="nounderline abstract_t">Savarino E, Zentilin P, Tutuian R, et al. The role of nonacid reflux in NERD: lessons learned from impedance-pH monitoring in 150 patients off therapy. Am J Gastroenterol 2008; 103:2685.</a></li><li><a class="nounderline abstract_t">ASGE Technology Committee, Wang A, Pleskow DK, et al. Esophageal function testing. Gastrointest Endosc 2012; 76:231.</a></li></ol></div><div id="topicVersionRevision">Topic 2248 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15753524" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Weakly acidic reflux in patients with chronic unexplained cough during 24 hour pressure, pH, and impedance monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18564161" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Impedance detected abnormal bolus transit in patients with normal esophageal manometry. Sensitive indicator of esophageal functional abnormality?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23621545" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Viscous impedance is an important indicator of abnormal esophageal motility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15017488" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Esophageal function testing with combined multichannel intraluminal impedance and manometry: multicenter study in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16984537" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Multichannel intraluminal impedance for the assessment of post-fundoplication dysphagia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15180718" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Combined multichannel intraluminal impedance and manometry clarifies esophageal function abnormalities: study in 350 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16393211" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Multichannel intraluminal impedance monitoring in the evaluation of patients with non-obstructive Dysphagia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15017607" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clarification of the esophageal function defect in patients with manometric ineffective esophageal motility: studies using combined impedance-manometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16542281" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Symptom and function heterogenicity among patients with distal esophageal spasm: studies using combined impedance-manometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17335450" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : ACG practice guidelines: esophageal reflux testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16189367" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Evaluation and management of laryngopharyngeal reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16368491" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Gastroesophageal and pharyngeal reflux detection using impedance and 24-hour pH monitoring in asymptomatic subjects: defining the normal environment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16899836" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Nonacid reflux in patients with chronic cough on acid-suppressive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19281866" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Efficacy of esophageal impedance/pH monitoring in patients with refractory gastroesophageal reflux disease, on and off therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37734911" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Updates to the modern diagnosis of GERD: Lyon consensus 2.0.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15194656" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15180722" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11375942" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Normal values for ambulatory 24-h combined impedance-pH monitoring on acid suppressive therapy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23142603" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Normal values of pharyngeal and esophageal 24-hour pH impedance in individuals on and off therapy and interobserver reproducibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7958686" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15667480" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Reproducibility of multichannel intraluminal electrical impedance monitoring of gastroesophageal reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16556669" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16848801" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17051602" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18356117" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18424190" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The utility of intraluminal impedance in patients with gastroesophageal reflux disease-like symptoms but normal endoscopy and 24-hour pH testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18445095" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Characteristics of symptomatic reflux episodes on Acid suppressive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18775017" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The role of nonacid reflux in NERD: lessons learned from impedance-pH monitoring in 150 patients off therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22657403" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Esophageal function testing.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
